Search | Clinical Trials Finder

Conditions: Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
Interventions: Samples; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions: Elafibranor, Placebo; Drug
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 2,157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 153
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 98 more

Conditions: Non Alcoholic Steatohepatitis (NASH)
Interventions: Tropifexor, Licogliflozin, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 28
States / cities: Dothan, Alabama • Coronado, California • Los Angeles, California + 23 more

Conditions: Fatty Liver, NAFLD
Interventions: ELF Test; Diagnostic Test
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: Survodutide, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 36
States / cities: Huntsville, Alabama • Coronado, California • Huntington Park, California + 31 more

Conditions: Non-Alcoholic Steatohepatitis (NASH)
Interventions: IVA337, Placebo; Drug
Lead sponsor: Inventiva Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 14
States / cities: Madison, Alabama • La Jolla, California • Los Angeles, California + 10 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: IVA337, Placebo; Drug
Lead sponsor: Inventiva Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 194
States / cities: Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more

Conditions: Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
Interventions: Not listed
Lead sponsor: Fibronostics USA, Inc; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Timeline: 2025
U.S. locations: 1
States / cities: Lady Lake, Florida

Conditions: Hepatic Impairment
Interventions: Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Indianapolis, Indiana • San Antonio, Texas

Conditions: Decompensated Cirrhosis
Interventions: Emricasan (25 mg), Emricasan (5 mg), Placebo; Drug
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 76
States / cities: Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 59 more

Conditions: Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty, Non-alcoholic Fatty Liver Disease (NAFLD), Endoscopic Ultrasound, Liver Function, Obesity, Liver Fibroses
Interventions: Insulin Resistance, Quality of Life Assessment, Liver Function Test, Radiologic features of NASH, Serologic features of NASH; Diagnostic Test · Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: AZD2693, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 16
States / cities: Chula Vista, California • La Mesa, California • Montclair, California + 11 more

Conditions: NAFLD
Interventions: Dietary intervention with very low calorie diet (VLCD), Control Arm; Dietary Supplement · Other
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD
Interventions: Rencofilstat, Placebo; Drug
Lead sponsor: Hepion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 39
States / cities: Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 33 more

Conditions: Hepatitis
Interventions: Metformin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Moderate Liver Impairment, Severe Liver Impairment
Interventions: BMS-986036; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Fatty Liver, Cirrhosis
Interventions: 13C-Methacetin, Breath ID Machine; Drug · Device
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis, Cirrhosis, Fatty Liver, Obesity, Childhood, Bariatric Surgery Candidate
Interventions: Not listed
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 7 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2099
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Nonalcoholic Steatohepatitis
Interventions: GR-MD-02, Placebo; Drug
Lead sponsor: Galectin Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: NASH With Fibrosis, MASH With Fibrosis
Interventions: Efruxifermin, Placebo; Drug
Lead sponsor: Akero Therapeutics, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 200
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 160 more

Conditions: Non-alcoholic Fatty Liver Disease, Liver Cirrhosis
Interventions: CC-90001, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 64
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more

Conditions: Liver Fibrosis Due to NASH
Interventions: Placebo, SIM; Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 41
States / cities: Phoenix, Arizona • Coronado, California • San Diego, California + 35 more

Conditions: Hepatic Failure, Liver Failure
Interventions: 0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose; Drug
Lead sponsor: Cardiox Corporation; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions: Velacur; Device
Lead sponsor: GI Alliance; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Flowood, Mississippi • Webster, Texas

Search by objective public record fields.

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.

The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology

A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

Phase 2b Study in NASH to Assess IVA337

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.

Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)

A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD

A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis

Treating Nonalcoholic Steatohepatitis (NASH) With Metformin

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

Development of a Breath Test for Monitoring Patients With Liver Disease

Blood Collection Biorepository for Liver Disease Research

Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

Cardiox Liver Function Test Pivotal Trial

Validation Study of the Velacur System in Comparison to MRE & MRI-PDFF in Patients With (Suspected) Liver Disease